Back to top
more

Catalent (CTLT)

(Delayed Data from NYSE)

$55.80 USD

55.80
1,453,462

-0.01 (-0.02%)

Updated May 13, 2024 04:00 PM ET

After-Market: $55.80 0.00 (0.00%) 5:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (94 out of 251)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Catalent's (CTLT) Latest Buyout to Expand Its Global Footprint

Catalent's (CTLT) latest acquisition is likely to significantly enhance its global Biologics business.

Here's Why Catalent (CTLT) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Catalent's (CTLT) New Project Completion Expands Global Footprint

Catalent's (CTLT) latest facility transformation is likely to significantly enhance the global Biologics business.

Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

Smart Beta ETF report for PBE

Reasons to Retain Catalent (CTLT) Stock in Your Portfolio

Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism on the stock.

Catalent's (CTLT) New Tie-Up to Provide Better Patient Access

Catalent's (CTLT) latest collaboration is expected to enable it to provide customers access to the TFF technology.

Catalent (CTLT) Down 3.4% Since Last Earnings Report: Can It Rebound?

Catalent (CTLT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Catalent (CTLT) Q2 Earnings Top Estimates, FY22 View Up

Catalent's (CTLT) robust performance across most of its segments drives its second-quarter fiscal 2022 top line.

Catalent (CTLT) Surpasses Q2 Earnings and Revenue Estimates

Catalent (CTLT) delivered earnings and revenue surprises of 7.14% and 5.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

McKesson (MCK) Hits 52-Week High: What's Aiding the Stock?

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

Accuray (ARAY) Q2 Earnings Miss Estimates, Margins Down

Accuray (ARAY) registers growth in Products revenues during fiscal Q2, thereby partly driving its overall top line.

NextGen Healthcare (NXGN) Beats on Q3 Earnings, Ups FY22 View

NextGen Healthcare's (NXGN) fiscal third-quarter earnings reflect strength in both of its revenue sources.

Catalent (CTLT) Earnings Expected to Grow: Should You Buy?

Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Catalent (CTLT) to Report Q2 Earnings: What's in the Cards?

Catalent's (CTLT) Biologics segment is likely to have maintained its impressive performance over the past few months, thereby aiding Q2 results.

Here's Why You Should Retain Masimo (MASI) Stock For Now

Investors continue to be optimistic about Masimo (MASI) owing to its focus on patient monitoring.

BD (BDX) Hits a New 52-Week High: What's Behind the Rally?

A slew of strategic acquisitions are driving the top line for BD (BDX).

Nevro's (NVRO) Senza Gets FDA Nod for Expanded Labeling for NSRBP

Nevro's (NVRO) receipt of the FDA's approval for expanded labeling of its Senza SCS System is expected to cater to underserved patients.

3 Reasons to Add Catalent (CTLT) Stock to Your Portfolio

Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism on the stock.

Catalent (CTLT) to Advance Oral Drug Development With New Launch

Catalent's (CTLT) Xpress Pharmaceutics service offers a quicker alternative to the traditional clinical development model, lowering the time needed to complete clinical studies.

PacBio (PACB) Reports Impressive Preliminary Q4, FY21 Revenues

PacBio's (PACB) solid fourth-quarter results are likely to have been boosted by strong segmental performances and robust placement of Sequel systems.

Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

Smart Beta ETF report for PBE

AMN Healthcare (AMN) Reports Solid Preliminary Q4 Revenues

AMN Healthcare's (AMN) solid fourth-quarter results are likely to have been boosted by solid segmental performances.

Masimo (MASI) Provides FY22 View, Preliminary FY21 Results Solid

Masimo's (MASI) solid full-year results likely to have been boosted by strong product sales.

Here's Why You Should Retain Abiomed (ABMD) Stock For Now

Investors remain optimistic about Abiomed (ABMD) due to its Impella product line's strength.